我是新手,想买GNBT

木嘴

GNBT 动了。。。。

木嘴

我在0.68 进了2000 unit

爱云儿

有去了解这间公司,本是打算买了就卖的,看来要先HOLD着先。

韦一笑

看来有起色了。。。。

葉芬

我的1.02 x 3粒 會Hold 著。
看情形還有得炒。

wobushi

原帖由 木嘴 于 9-6-2009 02:36 AM 发表
我在0.68 进了2000 unit

不错下，捉到底点。。。。。。

wobushi

原帖由 napster 于 9-6-2009 01:48 AM 发表
小妹吓到睡不下，你还敢这么说他。。。。
玩美国股一定要有holding power...

非常赞成。
我一开始进美股就买600股LVS @ 6. 50++, 之后就开始跌到2.50++，纸上就损失了近一万马币。。
虽然跌到这样，我还是想买多点来平均。
不过进钱后，LVS 起到4.50++, 就没有买。

wobushi

原帖由 napster 于 9-6-2009 01:48 AM 发表
小妹吓到睡不下，你还敢这么说他。。。。
玩美国股一定要有holding power...

非常赞成。
我一开始进美股就买600股LVS @ 6. 50++, 之后就开始跌到2.50++，纸上就损失了近一万马币。。
虽然跌到这样，我还是想买多点来平均。
不过进钱后，LVS 起到4.50++, 就没有买。

葉芬

GNBT 今晚Pre-Market走勢不錯。

葉芬

Jun 9, 2009, 8:30 a.m. EST
Generex Presented Positive Study Data At the American Diabetes Association Scientific Sessions

WORCESTER, Mass., Jun 9, 2009 (GlobeNewswire via COMTEX) -- Generex Biotechnology Corporation /quotes/comstock/15*!gnbt/quotes/nls/gnbt  (GNBT  0.87, +0.12, +16.00%)  (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that data in respect of two of its products was presented at the American Diabetes Association's (ADA's) 69th Annual Scientific Sessions held in New Orleans June 5 - 9, 2009.

As part of the session on New Concepts on Insulin Delivery Applications, independent clinician Professor Paolo Pozzilli, Head of the Department of Diabetes and Endocrinology at University Campus Bio-Medico, Rome, Italy, made a podium presentation of his abstract entitled Buccal Spray Insulin for the Management of Post-Prandial Hyperglycaemia in Subjects with Impaired Glucose Tolerance.

Postprandial hyperglycaemia (PPHG) occurs as the consequence of a reduced early insulin response after a meal and has been linked with an increased risk of cardiovascular events and raised mortality risk. Subjects with PPHG often present with dyslipidaemia, hypertension, abdominal obesity, microalbuminuria, endothelial dysfunction and markers of inflammation. The objective of this phase II study was to investigate the safety and efficacy of treatment with Generex Oral-lyn(tm), the Company's proprietary oral insulin spray product, on post-prandial plasma glucose excursions and insulin levels in subjects with impaired glucose tolerance (IGT). 15 subjects with IGT were included in the study. Subjects were randomized to take 4, 6 or 12 Generex Oral-lyn(tm) puffs, split in two doses each, before and 30 minutes after a standard oral glucose tolerance test (OGTT). Glucose excursions and insulin levels were measured at baseline and at 30, 60, 90, 120 and 180 minutes. There were no significant differences in glucose levels during OGTT with 4 or 6 Generex Oral-lyn(tm) doses compared to baseline OGTT. Treatment with 12 doses was followed by a significant 31.2% decrease in mean plasma glucose at two hours and a 28.4% decrease at three hours. Considering all time points of OGTT, there was a mean reduction of 16.5% in plasma glucose levels. There was a trend for increased insulin levels at all measurements reaching statistical significance at 30 minutes. No adverse events were observed during the study period. The study demonstrates that treatment with Generex Oral-lyn(tm) is a simple and valuable therapy for PPHG in subjects with IGT.

"With the explosion in the number of people with diabetes and pre-diabetes, now estimated to be 43% of the United States population over the age of 20, effective intervention will be required to address the significant attendant cardiovascular risks in the coming years," said Dr. Gerald Bernstein, the Company's Vice-President for Medical Affairs. "These study results suggest that Generex Oral-lyn(tm) could play a valuable role in the treatment regimen."

In addition, an abstract entitled A Novel Tool to Control Hypoglycaemia and Improve HbA1c in Very Young Children with Type 1 Diabetes, which featured Glucose RapidSpray(tm), the Company's proprietary glucose buccal spray product, was a poster presentation at the 2009 ADA scientific sessions.

Hypoglycaemia continues to be a complex condition to tackle, especially in children because of difficulties in administering glucose as well as child compliance. The aim of this study was to evaluate the effect of administering small amounts of glucose through Glucose RapidSpray(tm) (GRS) during first signs of hypoglycaemia in children affected by type 1 diabetes (T1D) to evaluate if such treatment was able to improve the metabolic control over a period of 9 months. GRS consists of a 19 ml bottle containing 10 g glucose solution with the addition of artificial flavors and excipients to facilitate buccal absorption, delivering glucose by spray in quantities as small as 0.5 grams. The trial was comprised of 27 T1D children up to 5 years of age. They were randomly allocated into two groups: A) GRS (10-20 puffs of GRS, 0.5 g to 1 g glucose) depending on hypoglycaemic symptoms; and B) traditional treatment of hypoglycaemia episodes (sugar, fruit juice, etc). The following parameters were evaluated at entry into the trial, at three months, at six months, and at the end of the study: HbA1c, number of hypoglycaemic episodes, compliance to treatment, and quality of life of children and parents. After three months, both groups showed a significant improvement in HbA1c with no differences between groups which further improved at 6 months, and at the end of the study. There was a statistically significant difference in the improvement of the HbA1c in the GRS treated group versus the control group. Finally, children in group A showed a tendency for less severe hypoglycaemic episodes during the day compared to group B in the observational period. A more acceptable and practical tool to manage hypoglycaemia, especially in toddlers, represents a very relevant therapeutic issue. GRS is able not only to reduce the risk of hypoglycaemia but to improve the overall metabolic control as shown by a reduction of HbA1c.

"The great value of GRS in this particular population, in addition to addressing hypoglycaemia, is that it is designed to allow parents to administer glucose in a specific and controlled fashion thereby providing considerable security and empowerment," observed Dr. Bernstein.

LaLaHem

买GNBT，会不会不如买GeoPharma的好呢？
由于资金有限，有什么股有高风险高回筹的介绍？
除了近期那些大公司外，医药业的好像在博罢了哦。

软趴趴

全职员工才27个的公司好像不什么稳吧？

安古司

又不是production部门，要酱多员工来打杂咩
重“质”不重“量”懂没有

安古司

hmm。。。
http://finance.yahoo.com/news/Generex-Biotechnology-apf-15516221.html?.v=1

各位大大作何感想？

wobushi

Fxxx, 拜五太累早睡，miss掉丢票机会。
拜一应该会掉。。

葉芬

GNBT 昨晚的Volume很大，今天應該有些作為。

葉芬

昨晚買多3粒 @ 0.62。
目前手上共有6粒，平均價 0.82。

nehooi05

原帖由 葉芬 于 17-6-2009 11:43 AM 发表
昨晚買多3粒 @ 0.62。
目前手上共有6粒，平均價 0.82。

我也猜会再炒它
买进了一些

葉芬

分享：GNBT將要飛了。。。

Power Ratings Chart 網站給 GNBT的Ratings是 “9”。

http://charts.tradingmarkets.com/prcharts/index.cfm?sym=GNBT


自己看著辦吧。

葉芬

分享： http://billiondollarmission.blog ... yzed-gnbt-wave.html

Friday, June 19, 2009
Reader Choice - Stocks Analyzed - GNBT, WAVE
Posted by ~ On a Mission at 6:24 PM

WAVE: I Love it!



I really love just about everything here, there is a solid trendline forming, the fundamentals look good, the news is good, overall A+ stock in my books right now. I got in to this stock at .35, and expect to sell two thirds of my shares at 1.50, and the remainder at 5.

There does indeed seem to be some short term weakness, but the overall market pulled back just the same, it is not specific to this stock. I would expect to see it bounce off that trendline again before heading back up, monday and tuesday some small gains, and then maybe a wednesday spike!

This sector is also performing wonderfully at the moment, with major cash flowing in (communications eqipment).

For what its worth, this is a STRONG buy for me.